Metastatic small cell lung cancer - an aggressive disease: a case report and literature review.
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
pubmed:
8
7
2021
medline:
4
2
2022
entrez:
7
7
2021
Statut:
ppublish
Résumé
In the present case study, we describe a 53-year-old male with an aggressive small cell lung cancer (SCLC) that was diagnosed in January 2019. Our patient was treated as first line of systemic chemotherapy consisting of cisplatin and etoposide followed by mediastinal prophylactic radiotherapy with good response later he received for his metastatic disease (M-SCLC) a rechallenge of systemic chemotherapy consisting of carboplatin, etoposide and dulvalumab with stable disease and after progression his disease he was treated with lurbinectedin and after four cycles he reached a complete radiologic response. To the best of our knowledge, this is the first case to be reported of M-SCLC patient treated with prior of two types of platinum combination with immunotherapy and reaching a complete radiologic response.
Identifiants
pubmed: 34232947
doi: 10.1097/CAD.0000000000001119
pii: 00001813-202112000-00022
doi:
Substances chimiques
Platinum Compounds
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1138-1141Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016; 893:1–19.
Bade BC, Dela Cruz CS. Lung cancer 2020 epidemiology, etiology, and prevention. Clin Chest Med 2020; 41:1–24.
Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am 2019; 103:463–473.
Kalemkerian GP, Schneider BJ. Advances in small cell lung cancer. Hematol Oncol Clin North Am 2017; 31:143–156.
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQM, Downey RJ, et al. Small cell lung cancer: clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw 2013; 11:78–98. doi: 10.6004/jnccn.2013.0011
doi: 10.6004/jnccn.2013.0011
Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc 2019; 94:1599–1622.
Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol 2019; 12:1–11.
Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist 2010; 15:187–195.
Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010; 35:202–215.
Liu D, Wang S, Bindeman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol 2017; 10:1–6.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Angeles Sala M, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020; 21:645–654.
Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer 2017; 117:628–638.
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 2020; 150:90–96.
Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, et al. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann Oncol 2017; 28:2559–2566.
Cavalieri S, Nichetti F, Morelli D, de Braud F, Martinetti A, Sottotetti E, et al. Pro-GRP in small cell lung cancer. Ann Oncol. 2017; 28:ii18doi: 10.1093/annonc/mdx088.006
doi: 10.1093/annonc/mdx088.006
Muley T, Zhang X, Holdenrieder S, Korse CM, Zhi XY, Molina R, et al. A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. Tumour Biol 2020; 42:1010428320958603.
Cavalieri S, Morelli D, Martinetti A, Galli G, Nichetti F, de Braud F, Platania M. Clinical implications for pro-GRP in small cell lung cancer. A single center experience. Int J Biol Markers 2018; 33:55–61.